Atopic Dermatitis: Important Advances in JAK Treatments

Atopic Dermatitis: Important Advances in JAK Treatments - Pre-Activity Survey

CME/CE Information

Activity Progress
Pre-Activity Survey
Page 1
Post-Activity Survey
CME Evaluation/Print Certificate

What is the mechanism of Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis (AD)? * Decrease pro-inflammatory cytokines
Increase platelet activation
Mimic interleukin-31 (IL-31)
Stimulate production of natural killer cells
Not sure
Which statement regarding clinical trial data for JAK inhibitors for AD is TRUE?* Abrocitinib 100 mg performed similar to placebo at 12 weeks, with 8% of patients in both groups achieving “clear” or “almost clear” responses
In a head-to-head trial of abrocitinib versus dupilumab or placebo, abrocitinib 200 mg demonstrated a longer time to take effect and less efficacy in controlling AD compared to dupilumab
Once-daily upadacitinib resulted in up to 70% (15 mg) to 80% (30 mg) of patients achieving “clear” or “almost clear” at 16 weeks
Ruxolitinib 1.5% cream resulted in 20% of patients achieving a 2-grade improvement in symptom control at the end of 8 weeks in both phase 3 trials
Not sure
Which patient would be the best candidate for JAK inhibitor therapy for AD based on patient-specific characteristics?* 50-year-old male with recurrent staphylococcal skin infections requiring antibiotics and diabetes
52-year-old male with a family history of rheumatoid arthritis
54-year-old female who smokes and was hospitalized for a pulmonary embolism 3 months ago
56-year-old female with a history of a transient ischemic attack last year
Not sure
A 30-year-old female is experiencing moderate AD symptoms, including itchy patches of skin on her arms and feet that are affecting her quality of life. She has tried low-potency corticosteroids, topical calcineurin inhibitors, and dupilumab, without success. She prefers topical administration when available. Which of the following agents would be best to try for her AD?* Abrocitinib
Infliximab
Ruxolitinib
Omalizumab
Not sure

Save and Proceed

Atopic Dermatitis: Important Advances in JAK Treatments

Linda Stein Gold, MD
Release Date: November 15, 2022
Expiration Date: November 15, 2023

Continue to Activity

Statement of Need/Program Overview

Are you familiar with the role of Janus kinase (JAK) inhibition in atopic dermatitis (AD)? Can you determine the place in therapy of JAK inhibitors for inadequately controlled AD based on the latest evidence? In this CliniClip activity, dermatology expert Linda Stein Gold, MD, reviews the rationale of JAK inhibition in the management of AD, discusses the latest clinical trial data surrounding JAK inhibitors in this setting, and explores how to individualize treatment plans in consideration of JAK inhibitors.

Target Audience
Dermatologists, dermatology nurse practitioners, dermatology physician assistants, and pharmacists involved in the care of patients with AD

Learning Objectives
Upon completion of this activity, learners should be better able to:

DESCRIBE the rationale for JAK inhibition for the treatment of inadequately controlled AD
DISCUSS the most recent clinical trial data on approved and emerging JAK inhibitors
DEVELOP individualized treatment plans with a risk-based consideration for novel JAK inhibitors for patients with inadequately controlled AD

Faculty

Linda Stein Gold, MD (Chair)
Director of Dermatology Clinical Research
Henry Ford Health System
Department of Dermatology
Detroit, MI
Division Head Dermatology
West Bloomfield, MI

Providership & Support

This educational activity is directly provided by Rush University Medical Center and Spire Learning.

This activity is supported by an independent educational grant from Incyte Corporation.

Conflicts of Interest Statement

As a provider of continuing education, Rush University Medical Center asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the start of the activity. All information disclosed must be shared with the participants/learners prior to the start of the educational activity.

Faculty
Linda Stein Gold, MD (Chair)
Director of Dermatology Clinical Research
Henry Ford Health System
Department of Dermatology
Detroit, MI
Division Head Dermatology
West Bloomfield, MI

Disclosure
Research Support: AbbVie Inc; Arcutis Biotherapeutics; Dermavant Sciences, Inc; Eli Lilly and Company; Incyte Corporation; LEO Pharma; Pfizer Inc
Speakers Bureau: AbbVie Inc; Arcutis Biotherapeutics; Dermavant Sciences, Inc; Eli Lilly and Company; Incyte Corporation; LEO Pharma; Pfizer Inc
Consultant: AbbVie Inc; Arcutis Biotherapeutics; Dermavant Sciences, Inc; Eli Lilly and Company; Incyte Corporation; LEO Pharma; Pfizer Inc

All of the relevant financial relationships have been mitigated.

Educational Planning Committee
Spire Learning Disclosures
Mairead Early (Program Manager), Allison Goldberg, MPA (Senior Director, Grants and Education), and Ashton Webb, PharmD, BCACP (Clinical Director) have no relevant financial relationship with an ACCME-defined ineligible company in the past 24 months.

Reviewers

Shilpa Mehta, MD, FAAD (Peer Reviewer)
Assistant Professor
Rush University Medical Center
Attending Physician, Division of Dermatology
Department of Medicine
John H. Stroger, Jr. Hospital of Cook County
Chicago, IL

Disclosure
The remaining course director(s), planner(s), faculty, and reviewer(s) of this activity have no relevant financial relationship(s) with ineligible companies to disclose.

Disclosure of Unlabeled or Investigational Use
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Privacy Policy
The Office of Interprofessional Continuing Education follows Rush University Medical Center’s Web privacy policy. Respect for the privacy of others is an important component of our institution’s policy and guidelines.

Rush collects only the information necessary to provide registrants with the services they request. When visitors register for activities, we ask for information about their identity to maintain a record of their participation. Registrants may be contacted if there is a problem with the registration (for instance, if there is a duplicate registration for the same activity, or if there is a question about information submitted). Participants may be asked to submit a knowledge test following completion of an online course; this is so that we may provide evaluation and feedback concerning the participant’s understanding of the content. In addition, participants have the opportunity to evaluate activities to help us improve these and future ones using an online form on our site. Completing the form is voluntary, and participants have the option to submit forms without personally identifiable information.

Commercial Support: Rush University is responsible for all financial decisions related to any qualified continuing education activity through the office of IPCE. The IPCE office must review and approve all decisions in concert with course leadership regarding the disposition and disbursement of commercial support in accordance with Joint Accreditation criteria.

Commercial Interest organizations providing financial or in-kind support for continuing education may not participate in any component of the planning process of an educational activity, including:

Assessment of learning needs
Determination of objectives
Selection or development of content
Selection of planners, presenters, authors and/or content reviewers
Selection of teaching/learning strategies
Evaluation methods

We do not share information about participants with anyone outside Rush without the participant’s explicit consent unless we have a good faith belief that we are required by law to disclose such information. We offer a number of online courses through third-party providers; Rush is not responsible for their privacy policies. It is the participant’s responsibility to learn the privacy and data collection policies of these third-party providers.

Rush University Medical Center and Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, address, phone number and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Rush University Medical Center and Spire Learning, LLC to continuously improve the learning experience.

Rush University Medical Center and Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Rush and Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

Copyright Information
Copyright © 2022 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and Rush University Medical Center will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.

Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Credit Designation Statement

Rush University Medical Center designates this enduring material activity for a maximum of (0.5) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

How to Receive Credit

There are no fees to participate in this educational activity. To receive credit:
• Read the learning objectives, disclosure statements, and other introductory CME information
• Complete the pre-assessment prior to the start of the activity
• Participate in the online enduring activity

• Submit the post-assessment with a passing grade of 75% or higher, and evaluation at the conclusion of the activity

If you are seeking credit, you must complete the post-assessment and evaluation at the conclusion of the activity.

For information about the accreditation of this activity, please contact Rush University Medical Center at ce_office@rush.edu or 312-942-7119.

For technical assistance, please contact Spire Learning at mearly@spirelearning.com.

Atopic Dermatitis: Important Advances in JAK Treatments - Pre-Activity Survey

Atopic Dermatitis: Important Advances in JAK Treatments

References for Atopic Dermatitis: Important Advances in JAK Treatments